QQQ   320.11 (-0.51%)
AAPL   165.14 (-0.13%)
MSFT   280.23 (-0.95%)
META   170.73 (+2.17%)
GOOGL   117.47 (+0.00%)
AMZN   138.93 (-1.33%)
TSLA   873.77 (+1.07%)
NVDA   175.35 (-7.66%)
NIO   20.24 (+0.10%)
BABA   90.58 (-2.14%)
AMD   99.90 (-2.36%)
MU   61.46 (-1.60%)
T   18.03 (-1.74%)
CGC   3.16 (+17.04%)
GE   75.34 (+1.32%)
F   15.85 (+3.59%)
DIS   109.01 (+2.23%)
AMC   23.65 (+6.63%)
PYPL   96.42 (+1.15%)
PFE   49.33 (+0.12%)
NFLX   233.60 (+3.01%)
QQQ   320.11 (-0.51%)
AAPL   165.14 (-0.13%)
MSFT   280.23 (-0.95%)
META   170.73 (+2.17%)
GOOGL   117.47 (+0.00%)
AMZN   138.93 (-1.33%)
TSLA   873.77 (+1.07%)
NVDA   175.35 (-7.66%)
NIO   20.24 (+0.10%)
BABA   90.58 (-2.14%)
AMD   99.90 (-2.36%)
MU   61.46 (-1.60%)
T   18.03 (-1.74%)
CGC   3.16 (+17.04%)
GE   75.34 (+1.32%)
F   15.85 (+3.59%)
DIS   109.01 (+2.23%)
AMC   23.65 (+6.63%)
PYPL   96.42 (+1.15%)
PFE   49.33 (+0.12%)
NFLX   233.60 (+3.01%)
QQQ   320.11 (-0.51%)
AAPL   165.14 (-0.13%)
MSFT   280.23 (-0.95%)
META   170.73 (+2.17%)
GOOGL   117.47 (+0.00%)
AMZN   138.93 (-1.33%)
TSLA   873.77 (+1.07%)
NVDA   175.35 (-7.66%)
NIO   20.24 (+0.10%)
BABA   90.58 (-2.14%)
AMD   99.90 (-2.36%)
MU   61.46 (-1.60%)
T   18.03 (-1.74%)
CGC   3.16 (+17.04%)
GE   75.34 (+1.32%)
F   15.85 (+3.59%)
DIS   109.01 (+2.23%)
AMC   23.65 (+6.63%)
PYPL   96.42 (+1.15%)
PFE   49.33 (+0.12%)
NFLX   233.60 (+3.01%)
QQQ   320.11 (-0.51%)
AAPL   165.14 (-0.13%)
MSFT   280.23 (-0.95%)
META   170.73 (+2.17%)
GOOGL   117.47 (+0.00%)
AMZN   138.93 (-1.33%)
TSLA   873.77 (+1.07%)
NVDA   175.35 (-7.66%)
NIO   20.24 (+0.10%)
BABA   90.58 (-2.14%)
AMD   99.90 (-2.36%)
MU   61.46 (-1.60%)
T   18.03 (-1.74%)
CGC   3.16 (+17.04%)
GE   75.34 (+1.32%)
F   15.85 (+3.59%)
DIS   109.01 (+2.23%)
AMC   23.65 (+6.63%)
PYPL   96.42 (+1.15%)
PFE   49.33 (+0.12%)
NFLX   233.60 (+3.01%)
NASDAQ:SPRO

Spero Therapeutics - SPRO Stock Forecast, Price & News

$0.80
+0.01 (+0.63%)
(As of 08/8/2022 03:14 PM ET)
Add
Compare
Today's Range
$0.79
$0.95
50-Day Range
$0.68
$1.25
52-Week Range
$0.68
$19.87
Volume
7,345 shs
Average Volume
420,720 shs
Market Capitalization
$26.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
789.9% Upside
$7.50 Price Target
Short Interest
Healthy
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.15) to ($2.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

376th out of 1,293 stocks

Pharmaceutical Preparations Industry

163rd out of 619 stocks

SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SPRO shares. Cantor Fitzgerald dropped their target price on shares of Spero Therapeutics from $27.00 to $5.00 in a research report on Tuesday, May 17th. Berenberg Bank cut Spero Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, May 20th. Cowen downgraded Spero Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 4th. Finally, HC Wainwright dropped their price target on Spero Therapeutics from $37.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, May 23rd. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.33.

Spero Therapeutics Stock Performance

NASDAQ:SPRO traded up $0.10 during trading on Monday, reaching $0.90. The company's stock had a trading volume of 2,611 shares, compared to its average volume of 420,720. The business's fifty day moving average price is $0.89 and its 200-day moving average price is $4.87. Spero Therapeutics has a twelve month low of $0.68 and a twelve month high of $19.87. The firm has a market cap of $29.70 million, a price-to-earnings ratio of -0.25 and a beta of 1.95.

Spero Therapeutics (NASDAQ:SPRO - Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.14). Spero Therapeutics had a negative return on equity of 116.93% and a negative net margin of 792.03%. The company had revenue of $2.07 million for the quarter, compared to analysts' expectations of $2.85 million. During the same period in the prior year, the business earned ($0.66) EPS. As a group, sell-side analysts forecast that Spero Therapeutics will post -3.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors have recently bought and sold shares of SPRO. Vanguard Group Inc. boosted its holdings in Spero Therapeutics by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 1,373,928 shares of the company's stock valued at $11,953,000 after purchasing an additional 22,550 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Spero Therapeutics by 4.8% in the first quarter. Rock Springs Capital Management LP now owns 990,913 shares of the company's stock valued at $8,621,000 after buying an additional 45,600 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Spero Therapeutics by 9.6% during the first quarter. Dimensional Fund Advisors LP now owns 406,946 shares of the company's stock worth $3,540,000 after acquiring an additional 35,724 shares during the period. OUP Management Co. LLC purchased a new position in Spero Therapeutics in the fourth quarter worth $3,988,000. Finally, Royal Bank of Canada lifted its holdings in Spero Therapeutics by 7.4% in the first quarter. Royal Bank of Canada now owns 196,097 shares of the company's stock valued at $1,706,000 after acquiring an additional 13,502 shares during the period. 69.36% of the stock is owned by institutional investors and hedge funds.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

The Women Who Shaped Short-Term Rental History
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
5/16/2022
Today
8/08/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+3,419.7%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
4 Analysts

Profitability

Net Income
$-89,760,000.00
Net Margins
-792.03%
Pretax Margin
-792.03%

Debt

Sales & Book Value

Annual Sales
$18.26 million
Book Value
$2.73 per share

Miscellaneous

Free Float
28,407,000
Market Cap
$26.42 million
Optionable
Optionable
Beta
1.95

Key Executives

  • Dr. Ankit Mahadevia M.D. (Age 41)
    MBA, Co-Founder, Pres, CEO & Director
    Comp: $924.28k
  • Mr. Satyavrat Shukla C.F.A. (Age 50)
    CFO & Treasurer
    Comp: $788.84k
  • Ted Jenkins
    VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M. (Age 59)
    Chief Legal Officer
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Mr. Timothy Keutzer (Age 54)
    Chief Devel. Officer
  • Dr. Ian A. Critchley
    Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D.
    Head of Clinical Operations
  • Dr. Angela Talley
    Sr. VP of Clinical Devel.













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRO, but not buy additional shares or sell existing shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 12-month price targets for Spero Therapeutics' stock. Their SPRO stock forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.50 in the next year. This suggests a possible upside of 789.9% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How has Spero Therapeutics' stock price performed in 2022?

Spero Therapeutics' stock was trading at $16.01 at the start of the year. Since then, SPRO stock has decreased by 94.7% and is now trading at $0.8428.
View the best growth stocks for 2022 here
.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a increase in short interest in July. As of July 15th, there was short interest totaling 557,800 shares, an increase of 34.9% from the June 30th total of 413,600 shares. Based on an average daily volume of 713,200 shares, the short-interest ratio is currently 0.8 days. Approximately 2.3% of the shares of the stock are short sold.
View Spero Therapeutics' Short Interest
.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Monday, May, 16th. The company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.87) by $0.14. The business earned $2.07 million during the quarter, compared to analysts' expectations of $2.85 million. Spero Therapeutics had a negative net margin of 792.03% and a negative trailing twelve-month return on equity of 116.93%. During the same period last year, the company earned ($0.66) EPS.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.40%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $0.84.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $27.66 million and generates $18.26 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.